The effect of interferon alpha 2b on the treatment of basal cells cancer
Phase 2
Recruiting
- Conditions
- basal cell carcinoma.Malignant neoplasm of skin, unspecified
- Registration Number
- IRCT2017093017756N30
- Lead Sponsor
- Vice-chancellery for Research and Technology, Mashhad University of Medicla Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Informed written consent for participation; definitive diagnosis of basal cell carcinoma of skin in pathology; and age 18 years old or above. Exclusion criteria: Morphea-like basal cell carcinoma of skin; nodulo-ulcerative basal cell carcinoma; pregnancy and breast-feeding; previous history of severe complications with interferon alpha 2b; no intent to complete the treatment course; no intent to complete the follow-up period; previous history of cardiovascular disease; previous history of thromboembolic disease; local radiotherapy on the target region; previous history of arsenic exposure; and immune insufficiency.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response. Timepoint: Every two months. Method of measurement: Physical examination.
- Secondary Outcome Measures
Name Time Method eutropenia. Timepoint: on a weekly basis. Method of measurement: Complete blood count.;Headache. Timepoint: on a weekly basis. Method of measurement: Medical history.;Fatigue. Timepoint: on a weekly basis. Method of measurement: Medical history.;Pathologic response. Timepoint: Two months after completion of treatment. Method of measurement: Biopsy.;Fever. Timepoint: on a weekly basis. Method of measurement: Physical examination.